Atrial Fibrillation
📧 Sign up to get email alerts when something new happens for Atrial Fibrillation.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS safety_alert · 2026-03-12Clinical Trial Update: High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
Clinical trial update reporting high gastrointestinal bleed risk outcomes in patients with non-valvular atrial fibrillation (NVAF) in France…
-
EMA safety_alert · 2016-02-05EMA concludes defective device in ROCKET study does not impact Xarelto's safety
EMA states that a defective device in the ROCKET study does not impact the safety of Xarelto (rivaroxaban).
-
CLINICAL_TRIALS safety_alert · 2016-01-27Clinical Trial Update: Retracting the Esophagus During AF Ablation [NA]
The trial update highlights safety concerns about retracting the esophagus during atrial fibrillation ablation, including the risk of esopha…
-
CLINICAL_TRIALS safety_alert · 2012-03-21Clinical Trial Update: Safety of Amiodarone and Ranolazine Together in Patients With Angina [Phase 4]
Phase 4 clinical trial update evaluating the safety of co-administering amiodarone and ranolazine in patients with angina and related cardio…
-
EMA safety_alert · 2011-11-18European Medicines Agency updates on safety of Pradaxa
EMA updates safety information for Pradaxa (dabigatran) to reflect new risk signals and recommendations for monitoring and use.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA safety_alert · 2011-09-22European Medicines Agency recommends restricting use of Multaq
The EMA recommends restricting the use of Multaq (dronedarone) due to safety concerns and safer alternatives; explicit usage restrictions an…
-
EMA safety_alert · 2011-07-11European Medicines Agency reviews cardiovascular risk of Multaq
The European Medicines Agency is reviewing cardiovascular risk associated with Multaq (dronedarone) to assess safety in patients with atrial…